Beyond Medtech: Healthcare+ Expo Taiwan Sets New Stage for Global Innovation in Future AI Healthcare
1.12.2023 18:00:00 EET | Business Wire | Press release
The Healthcare+ Expo Taiwan, currently taking place at Nangang Exhibition Hall 1 from November 30 to December 3, 2023, is poised to redefine the landscape of AI healthcare on a global scale. This year's edition boasts the remarkable participation of 650 companies, occupying 2,300 booths, and has garnered the attention of leading technology firms and hospitals across the Asia-Pacific region.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231201062013/en/
Expand businesses into growing markets in the APAC region with Healthcare+ Expo Taiwan. Join medical institutes and companies in the fields of medtech, biotech and healthcare to promote products, build partnerships and seize supply-demand opportunities. (Graphic: RBMP & IBMI)
Taiwan's pivotal role in the AI-related supply chain is underscored by its impressive contribution, manufacturing AI chips, and over 90% of the world's AI servers. This proficiency positions Taiwan as a key player in driving substantial computing power, establishing it as an indispensable global collaborator in the realm of AI healthcare. The Expo is showcasing an extensive array of AI applications and solutions, encompassing AI infrastructure, cloud and high-performance computing servers, AI-enabled medical devices and diagnostics, and generative AI for workflow optimization. Participating medical centers from Taiwan, together with their IT/ICT sector partners and multinational giants such as Intel and Microsoft, aim to address healthcare challenges and foster interdisciplinary collaborations.
Anticipating the attendance of over 30,000 professionals from the Asia-Pacific region, Eastern Europe, and the Gulf, the organizer foresees substantial interest from industry associations in the United Arab Emirates, Poland, Czech Republic, as well as rapidly growing economies such as Malaysia, Philippines, Indonesia, Vietnam, and Thailand. Strategic partnerships with Taiwan's healthcare industry are in the spotlight, with more than 500 scheduled B2B meetings designed to facilitate trade discussions and catalyze new business ventures.
Distinguishing itself as the only trade fair globally with a focus on hospitals, Healthcare+ Expo has experienced consistent annual growth of 15% in event scale over its seven-year history. It has evolved into one of the most sought-after gatherings in the Asia-Pacific region for healthcare professionals. Concurrently, the Expo is hosting major events, including the MEDTEX Summit Asia and the Cancer Treatment and Precision Medicine in APAC forum.
The Healthcare+ Expo 2024 is scheduled for December 5 to 8, 2024, and will continue to serve as a catalyst for transformative advancements and collaborative breakthroughs in the ever-evolving landscape of AI healthcare.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231201062013/en/
Contact information
Media:
Institute for Biotechnology and Medicine Industry (IBMI); Research Centre for Biotechnology and Medicine Policy (RBMP)
Yu Chen (Katy) Chu, Project Manager
886 2 2655 7888 ext.627
katychu@rbmp.org.tw
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Merz Therapeutics and Kvvit Enter Exclusive Agreement for INBRIJA® (levodopa inhalation powder) in Mainland China, Hong Kong and Macao26.5.2026 10:00:00 EEST | Press release
Merz Therapeutics GmbH and Jiangxi Kvvit Pharmaceutical Co. Ltd. today announced that the companies have entered into an exclusive license and collaboration agreement regarding INBRIJA® (levodopa inhalation powder) and its proprietary inhalation device for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor in mainland China, Hong Kong and Macao. Under the agreement, Merz will supply INBRIJA® and retain responsibility for global product quality and key regulatory activities. Kvvit will lead development, regulatory activities and commercialization in the licensed territory under a jointly agreed China Development Plan. Merz will act as Overseas Holder of the Drug Registration Certificate and Kvvit will serve as Domestic Responsible Person, funding local clinical development and regulatory submissions. INBRIJA® is currently not approved in China, Hong Kong and Macao
Poland’s Poznan University of Technology Unveils IQM Quantum Computer to Drive Research and Education26.5.2026 09:49:00 EEST | Press release
Poznan University of Technology (PUT) has launched its first locally installed quantum computer, deployed by IQM Quantum Computers, to advance education and scientific research in the field of quantum technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525424085/en/ The moment Poland switched on IQM's second quantum computer. Minister of Science and Higher Education Dr. Marcin Kulasek, IQM CEO Jan Goetz and CCO Sylwia de Weydenthal, Rector of Poznań University of Technology Prof. Teofil Jesionowski, and industry leaders mark the occasion. The installation of the IQM Radiance R1 system at the university aligns with the strategic objectives outlined in Poland’s quantum technology development roadmap, as well as broader European initiatives in this area. Poland has a strong foundation in quantum technologies, particularly in STEM (Science, Technology, Engineering, and Mathematics) disciplines, built on high academic
BearingPoint Introduces Fully Sovereign On-Premise Infrastructure for GenAI and Agentic AI in Europe26.5.2026 09:30:00 EEST | Press release
BearingPoint announces the launch of the BearingPoint Fully-Owned Sovereign Infrastructure Stack, an infrastructure platform designed, operated, and managed entirely by BearingPoint for GenAI and agentic AI applications, consistently engineered for European sovereignty, compliance, and security. With its own data center in Graz, the solution enables companies and public institutions to run sensitive AI workloads in fully controlled, EU-based environments – from initial innovation projects to mission-critical scenarios. All data remains in Austria and therefore within European jurisdiction, helping organizations protect themselves from geopolitical risks, arbitrary price changes by international hyperscalers, and the risk of external shutdowns. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525934244/en/ With its own data center in Graz, the BearingPoint Fully-Owned Sovereign Infrastructure Stack enables companies and publ
Bial Announces Completion of Phase 2b ACTIVATE Study with BIA 28-6156 in GBA1-Associated Parkinson’s26.5.2026 09:00:00 EEST | Press release
Bial, an innovation-driven biopharmaceutical company focused on neurosciences and rare diseases, today announced the completion of the treatment period in its Phase 2b ACTIVATE study of BIA 28-6156 (pariceract) in patients with Parkinson’s disease (PD) who have a pathogenic mutation in the glucocerebrosidase 1 (GBA1) gene (GBA-PD). Upon completion of the 78-week double-blind treatment period and all scheduled safety follow-ups, data cleaning and analysis are currently ongoing. Topline results will be released around the end of Q2. A status report on the ACTIVATE study was presented in an oral presentation at the 3rd International GBA1 Meeting 2026. The team is currently attending the 7th World Parkinson Congress, taking place in Phoenix from 24 to 27 May 2026. “Momentum is building across the Parkinson’s scientific community around the clinical potential of pariceract. At the GBA1 Meeting and the 7th World Parkinson Congress, we have been able to connect with this community as we appro
Oticon Medical Introduces Ponto™ Instant, Expanding Non-Surgical Choice with Instant HearBand and Instant SoundConnector26.5.2026 08:00:00 EEST | Press release
Oticon Medical today announces its new non-surgical portfolio, Ponto Instant, designed to broaden access to bone conduction hearing and offer more choice for users and hearing care professionals. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260525771593/en/ Left: Instant HearBand, a discreet behind-the-head wearable solution that offers an alternative to Softband 5. Right: Instant SoundConnector, a small accessory fitted to a cap or other headwear, providing another non-surgical way to wear a Ponto sound processor. The Ponto Instant portfolio includes Softband 5, Oticon Medical’s established and trusted non-surgical solution, and now expands with the launch of Instant HearBand and Instant SoundConnector, further strengthening its wearable offering for children and adults who prefer a non-surgical solution. Instant HearBand: a discreet new wearable alternative As part of the new portfolio, Instant HearBand is introduced as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom